Fibrates: A Possible Treatment Option for Patients with Abdominal Aortic Aneurysm?

Naofumi Amioka, Toru Miyoshi

Research output: Contribution to journalComment/debatepeer-review

Abstract

Abdominal aortic aneurysm (AAA) is a life-threatening disease; however, there is no established treatment for patients with AAA. Fibrates are agonists of peroxisome proliferator-activated receptor alpha (PPARα) that are widely used as therapeutic agents to treat patients with hypertriglyc-eridemia. They can regulate the pathogenesis of AAA in multiple ways, for example, by exerting anti-inflammatory and anti-oxidative effects and suppressing the expression of matrix metallopro-teinases. Previously, basic and clinical studies have evaluated the effects of fenofibrate on AAA. In this paper, we summarize the results of these studies and discuss the problems associated with using fenofibrate as a therapeutic agent for patients with AAA. In addition, we discuss a new perspective on the regulation of AAA by PPARα agonists.

Original languageEnglish
Article number74
JournalBiomolecules
Volume12
Issue number1
DOIs
Publication statusPublished - Jan 2022
Externally publishedYes

Keywords

  • Abdominal aortic aneurysm
  • Fibrates
  • Macrophages
  • Matrix metalloproteinase
  • Oxidative stress
  • Peroxisome proliferator-activated receptor alpha

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Fingerprint

Dive into the research topics of 'Fibrates: A Possible Treatment Option for Patients with Abdominal Aortic Aneurysm?'. Together they form a unique fingerprint.

Cite this